Amondys 45
Phase 3Small molecule
Sarepta TherapeuticsAmondys 45 is one of 44 small molecule programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
125 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyPhase 3
Aldactone
PfizerPhase 3
Rifadin
SanofiPhase 3
Nolvadex
AstraZenecaPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Duvyzat
ItalfarmacoPhase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
ENSPRYNG
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amondys 45. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company